U.S. Markets closed
  • S&P 500

    +15.87 (+0.34%)
  • Dow 30

    -60.10 (-0.17%)
  • Nasdaq

    +72.14 (+0.45%)
  • Russell 2000

    -13.42 (-0.56%)
  • Gold

    -0.20 (-0.01%)
  • Silver

    -0.02 (-0.08%)

    -0.0006 (-0.0568%)
  • 10-Yr Bond

    -0.0150 (-0.94%)
  • Vix

    +0.48 (+2.81%)

    -0.0003 (-0.0216%)

    +0.0520 (+0.0455%)

    +492.30 (+0.91%)
  • CMC Crypto 200

    -65.80 (-4.48%)
  • FTSE 100

    -35.24 (-0.48%)
  • Nikkei 225

    +84.43 (+0.29%)

ORMP: Oramed announces positive results from cohort 2 of Phase 2 trial with ORMD-0801 in T2D patients

By Anita Dushyanth, PhD



Results of the Phase 2b Trial

The primary objective of the Phase II study was to explore therapeutic efficacy in patients and more importantly, determine the dose(s) and regimen for Phase III trials. A double blind, randomized 90-day dosing trial (Phase 2b), which was funded by ORMD, was designed to evaluate the efficacy of ORMD-0801 in decreasing HbA1C levels, a key clinical measure of blood sugar. On September 17, 2019, Oramed (NASDAQ:ORMP) announced that the last patient from the first cohort of the Phase 2b clinical trial of ORMD-0801 had completed treatment.

Cohort A: A total of 269 U.S. based patients with more than 6-months history of T2D and HbA1C levels between 7.5% and 9.6%, were enrolled in the Phase 2b trial. Approximately 70% of the randomized patients were on metformin alone, or metformin with up to two additional oral antihyperglycemic agents. Patients were randomized into three groups (~80 patients in each arm) to assess dosing frequency: once-daily (32mg/day), twice-daily (64mg/day), thrice-daily (96mg/day). Approximately 1/3rd of patients in each treatment arm were assigned to placebo. Two hundred nine (209) patients completed treatment to the 12-week endpoint and were included in the data analysis (24 subjects did not complete the full 12 weeks of treatment). In addition, due to evidence of treatment-by-center interaction, two sites (36 patients (13.4% of enrolled subjects)) were excluded from the statistical analysis.

The key outcomes to be assessed were reduction in HbA1c levels and safety. The secondary end points included safety assessed by hypoglycemia, change from baseline in glycemic parameters measured using outpatient CGM and change in weight from baseline to week 12 of the treatment period.

(Source: oramed.com)

Results demonstrated that 32mg dosed once and twice daily resulted in HbA1c reduction of 0.60% (0.54% with placebo adjustment, p-value 0.036) and 0.59% (0.53% with placebo adjustment, pvalue 0.042) by 12 weeks. The thrice-daily arm did not meet statistical significance (p-value 0.093).

ORMD-0801 demonstrated an excellent safety profile with no serious drug-related adverse events.

Results also demonstrated no increase in hypoglycemic events and no weight gain when compared to placebo.

Cohort B: The company has also initiated a second cohort of patients in a 90-day, double blind, randomized, multi-center study designed to evaluate the potential efficacy of multiple lower doses of ORMD-0801 with once daily higher dosing. The study was designed to identify the optimal dose of ORMD-0801 for the Phase 3 trial. In the low-dose second cohort, 78 patients have been randomized into five groups: 8 mg dosed once-daily; 8 mg dosed twice-daily; 16 mg dosed once-daily; 16 mg dosed twice-daily; and placebo dosed twice-daily. About 60% of the randomized patients were on two or more glucose-lowering medication. As anticipated, Oramed announced the results from the second cohort on February 27, 2020.

(Source: oramed.com)

Patients randomized in the trial treated with 8 mg of ORMD-0801 once daily achieved an observed mean reduction of 1.29% from baseline and a least square mean reduction of 0.95% from baseline, or 0.81% adjusted for placebo (p value = 0.028). Patients who had HbA1C readings above 9% at baseline and received 8 mg of oral insulin once daily experienced a 1.26% reduction in HbA1C levels by week 12. Treatment with ORMD-0801 at all doses demonstrated an excellent safety profile, with no serious drug-related adverse events and no increased frequency of hypoglycemic episodes or weight gain compared to placebo. The side-effect profile was no different from those that received a placebo. In particular, 8 mg once-daily and 16 mg twice-daily group reported no hypoglycemic events. Serum glucose levels were very consistent with HbA1C levels.

(Source: oramed.com)

The table above shows change in placebo-adjusted HbA1C values from baseline at 12 weeks for Cohort A and Cohort A&B together. In Cohort A, HbA1C levels post treatment (with 32mg dosed once, twice or thrice daily) were significantly lower in patients having baseline HbA1C values greater than 9, which is as expected. For those having HbA1C values less than or equal to 9, 32mg dosed once twice or thrice daily saw a smaller drop in values. When looking at values in Cohorts A and B, for those patients having baseline HbA1C values greater than 9, the placebo-adjusted numbers demonstrated significant change except for 16mg once daily dose that showed no change in values. Especially, the 8mg once daily showed an impressive reduction in levels by 1.26%. For those having HbA1C values less than or equal to 9, 8mg once or twice daily saw a smaller drop in values whereas the 16mg dose did not see a change.

ORMP-0801 has shown clinical efficacy. In fact, at 12 weeks after baseline treatment, we see significantly higher reduction in HbA1C levels among patients who were treated with 8mg doses as compared to the 16mg or 32mg doses. The 16mg twice daily and 32mg thrice daily showed reduction in levels after adjusting for placebo but were not statistically significant. It was further observed that, the increase in frequency of dosing did not show significant improvement in HbA1C levels. The present study further demonstrated no significant change in serum glucose levels at 12 weeks from baseline.

An effective oral form of insulin has benefits in terms of encouraging compliance and treatment adherence among patients. Physiologically such a dosage form replicates the natural route of insulin secretion and absorption through the portal vein and targets the liver directly. However, developing an oral form has, thus far, been challenging to the research community. Only a fraction of insulin administered by injections reaches the liver, often causing excess sugar to be stored in fat and muscle which results in weight gain. While the development of oral insulin has been elusive, Oramed has developed their candidate that overcomes the barriers to absorption and protect the insulin while transiting through the gastrointestinal (GI) tract. Due to direct engagement of the liver and resumption of its role in glucose metabolism, Oramed’s candidate has likely offered advantages with plausible beneficial clinical ramifications, including no change in weight gain associated with systemic insulin therapy and reducing the risk of hypoglycemia. In normal patients, glucose homeostatis is maintained. A transient increase in insulin secretion occurs just before dawn to control hepatic glucose production and prevent hyperglycemia. A major challenge T2D patients face is that they experience abrupt increases in fasting levels of plasma glucose or insulin requirements or both at dawn. One of the goals in treating T2D patients is to reestablish normal glycemic levels in the morning to lower the mean daily blood glucose and HbA1c levels. By improving night-time glucose levels, a person with diabetes can start the day with improved metabolic condition, which enables better control of blood glucose levels throughout the day. ORMD-0801 has demonstrated an excellent safety profile, specifically with regards to hypoglycemic events.

While many other competing firms have developed candidate drugs that fell by the wayside, ORMD-0801 has demonstrated efficacy that has not been achieved before. It also offers the secondary benefit of not having to inject oneself with medication every so often. ORMD-0801 could prove to be a game-changer for the more than 100 million Americans living with diabetes. During the investor call, Dr. Fleming expressed excitement over the positive clinical evidence of ORMD-0801.

Insulin drugs tend to have a narrow therapeutic index and a small difference in the dosage could result in a therapeutic benefit or toxicity. For instance, an overdose of insulin may cause severe hypoglycemia resulting in brain damage or even death. ORMD-0801 has shown safety and efficacy and is promising to address the unmet need in the treatment of diabetes. Although ORMD-0801 could be packaged at multiple doses, the outcome of the trial indicates that 8 mg dosed once-daily provided good overall clinical benefit. The study indicated that dosing frequency had little effect on the efficacy of ORMD-0801 T2D patients. A lower dose administered once daily also provides economic benefit to patients. Perhaps, the 8mg of insulin could prove to be a “one-size-fits-all” dose despite the enormous genetic variation among T2D patients. However, this is yet to be decided based on Phase 3 studies. Additionally, there is opportunity to use it as a treatment for T1D patients and even in prediabetics as a preventive medication.

The company hopes to be able to meet with the FDA for an end-of-Phase-2 meeting for feedback on the design for a Phase 3 trial. We believe that the success of this clinical study could fuel a partnership from a larger pharmaceutical company.

In order to push forward with the research and studies, Oramed needs additional capital. On February 27, 2020 ORMD announced public offering of 5.25 million shares of its common stock at a price of $4.00 per share. Oramed has also granted the underwriters a 45-day option to purchase up to 787,500 additional shares of common stock at the public offering price, less the underwriting discount. Aggregate proceeds from the offering are expected to be about $21 million.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.